ALPN — Alpine Immune Sciences Share News
0.000.00%
Last trade - 00:00- $4.46bn
- $4.15bn
- $58.88m
Brief: Alpine Immune Sciences Q1 EPS USD -0.28 Vs. IBES Estimate USD -0.41
Moves: Lazard hires veteran healthcare dealmaker Colocci as vice chairman
U.S. RESEARCH ROUNDUP-Cheesecake Factory, Netflix, Texas Roadhouse
US STOCKS-S&P 500, Nasdaq end sharply higher on soft inflation data, eyes on earnings
US STOCKS-S&P 500, Nasdaq end sharply higher on soft inflation data, eyes on earnings
US STOCKS-Wall Street rebounds on softer inflation data, eyes on earnings
U.S. STOCKS ON THE MOVE-Constellation Brands, Nike, Rocket Lab
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-DoorDash, Devon Energy, Arvinas
U.S. STOCKS ON THE MOVE-Rallybio, Alpine Immune, Marcus
Street View: Vertex's $4.9 bln Alpine Immune takeover expands its portfolio
Deals of the day-Mergers and acquisitions
Alpine Immune surges on Vertex Pharma's $4.9 bln takeover
U.S. RESEARCH ROUNDUP-Airbnb, Albemarle, Biogen
Press Digest: Wall Street Journal - April 11
Brief: Alpine Immune Sciences Says On Deal Termination Under Specified Conditions Co May Be Required To Pay Vertex Pharmaceuticals Termination Fee Of $173 Million
Brief: Alpine Immune Sciences Shares Updated Clinical Data From Povetacicept in IgA Nephropathy
Vertex Pharmaceuticals to buy Alpine Immune Sciences for $4.9 bln (updated)
Vertex to acquire Alpine Immune Sciences for $4.9 bln